Navigation Links
Data on Vivitrol for opioid dependence showed sustained efficacy over 18 months
Date:11/9/2011

DUBLIN, Ireland, Nov. 9, 2011 Alkermes plc (NASDAQ: ALKS) today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV. Results from the one-year, open-label extension of the six-month pivotal study showed sustained efficacy of VIVITROL, as measured by the number of opioid-free urine screens, in patients who received VIVITROL, in combination with psychosocial treatment, for a total of 18 months of treatment. Additionally, all safety events observed during the open-label extension were consistent with those set forth in the approved product labeling.

"The robust data from this extension study confirm VIVITROL's efficacy and safety profile over an 18-month period and support its clinical utility as a treatment option for opioid dependence, following opioid detoxification," stated Evgeny Krupitsky, M.D., Ph.D., Professor of Psychiatry, St. Petersburg State Pavlov Medical University and Head of the Department of Addictions at the Bekhterev Research Psychoneurological Institute. "VIVITROL is the first and only once-monthly medication that offers patients and physicians a non-narcotic treatment option to help fight this challenging disease."

During the total observation period of 18 months, improvements during the six-month pivotal trial observed in patients treated with VIVITROL were maintained for the duration of the subsequent one-year, open-label extension study. Half of the patients (49%) who entered the one-year extension study, after receiving six months of VIVITROL in the pivotal study, were completely abstinent for the duration of the extension study, based on opioid-free urine screens. The response profile based on the number of opioid-free urine screens was the primary efficacy endpoint of the six-month pivotal study. The extension study also measured opioid craving, improvements in quality of life measures, self-reported opioid use and incidence of physical opioid dependence, confirming the findings documented in the first phase of the study. All patients received psychosocial counseling.

Treatment with VIVITROL during this study showed a low rate of clinical adverse events, the absence of severe adverse events and a low overall rate (2.6%) of injection site pain, with no serious injection site reactions. All safety events observed during the open-label extension were consistent with those set forth in the approved product labeling. No patients discontinued the open-label extension due to serious adverse events. The most common clinical adverse events listed in the extension study were toothache and influenza.

Overall, nearly 65% of patients completed the open-label study, representing a high completion rate for an addiction study. At the onset of the study, 114 patients from the original six-month pivotal trial continued into the open-label, 52-week extension study. Sixty-seven patients continued treatment with VIVITROL, while 47 patients who had been on placebo crossed over to receive VIVITROL.


'/>"/>

Contact: Jennifer Snyder
781-609-6166
Alkermes plc
Source:Eurekalert

Related medicine news :

1. Inadequate access to opioid-based pain relief is a human rights issue for cancer patients
2. PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy
3. Improper use of opioids sparks a new Canadian practice guideline
4. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
5. New program targets research on reducing deaths due to prescription opioid overdose
6. Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows
7. Oxycontin, Other Opioid Painkillers Tied to Higher Health Risks
8. Study Finds Third of Cancer Patients on Opioids Are Confused
9. Follow-Up Deemed Lacking for People Taking Opioids
10. Analysis of opioid prescription practices finds areas of concern
11. FDA Looks to Crack Down on Misuse of Opioid Painkillers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... already work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement ... and cost of the care members and patients receive. The agreement also signifies ...
(Date:7/24/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated The Sharon Kleyne Hour ... Tears® EyeMist® recently talked on the air about an alarming Post magazine article of ... Zidor Aldama described the situation in which Chinese children are under pressure to perform ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... that they have enrolled over 100,000 children in their treatment program. Clubfoot is ... year in areas where treatment is limited or non-existent. Without intervention, these children ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, P.C. ... New York, (516) 784-5858. The office opened earlier this summer and is currently ... and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical director ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Center for Addiction Recovery ... will host a second Multiple Pathways of Recovery Conference on October 23-26, 2017. ... born from CCAR’s foundational principle – a belief in multiple pathways of recovery, ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
(Date:7/10/2017)... July 10, 2017  US medical equipment and supply ... according to Medical Equipment & Supplies: United ... Focus Reports. Continued increases in demand for medical services ... the population and supported by gains in disposable personal ... supplies. New product introductions will also drive sales as ...
Breaking Medicine Technology: